▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Brian Wilson

BiotechWilson

Shrewd biotech investor, research consultant, numbers guy.

Recent Articles by Brian Wilson

Jul 22, 2014 by Brian Wilson

Why Investors Continue to Flee Aegerion Stock

In theory Aegerion could still reach this peaks sales figure (quite easily) given that there are many more reimbursable HoFH patients out there, but it appears that Amgen’s (AMGN) hugely successful PCSK9 inhibitor evolocumab will dethrone Juxtapid before that happens.

Jul 15, 2014 by Brian Wilson

Ariad Stock's Biggest Risk Is Its Only Hope

f Ariad continued to see high rates of Iclusig-induced serious adverse events and/or deaths amongst cancer patients in its new trials, the stock could be in serious trouble.

Jul 14, 2014 by Brian Wilson

Up 33%: Is Vertex Pharmaceuticals Stock Overpriced?

Read below for more on this stock, which has climbed so much year-to-date and seems to potentially be priced to perfection.

Jul 8, 2014 by Brian Wilson

Is This the Crown Jewel of the ISIS Pipeline?

Perhaps the most promising target in the ISIS pipeline is ApoCIII – a protein that is responsible for transporting triglycerides in the blood.

Jun 30, 2014 by Brian Wilson

Why Teva's Magic Bullet Could Misfire

But with the recent loss of its lawsuit against the FDA's approval of these generic (which was meant to block competing glatiramer acetate formulations without additional bioequivalency trial data) it’s clear that the new 40 mg/mL formulation of Copaxone is now the only thing preventing Teva’s Copaxone brand from totally losing its market share in multiple sclerosis given its current price.

Jun 27, 2014 by Brian Wilson

Why I'm Still Avoiding Questcor

A total of seven litigations against Questcor are currently underway. Two of them - the Retrophin litigation and USAO litigation - represent very serious threats to the H.P. Acthar business model.

Jun 26, 2014 by Brian Wilson

Will Amgen’s Acquisition of Onyx Pay off Soon?

Perhaps the most important part of the Onyx acquisition was Kyprolis – a blood cancer drug that is currently being marketed as a last resort option for multiple myeloma patients.

Jun 24, 2014 by Brian Wilson

Pharma’s Huge Bet on Immunotherapies

Given the data that have been released so far, it appears that the discovery of the PD-1/PD-L1 mechanism is the single biggest technological leap in the immunotherapy space to date.

20120605104516378

Jun 23, 2014 by Brian Wilson

Bristol-Myers Squibb's Oncology Opportunity

But despite all the challenging facing Bristol-Myers today, I do believe the positioned to do extremely well in oncology due to the commercial potential of Sprycel (dasatinib) and Yervoy (ipilimumab). Both drugs have been growing sales rapidly throughout the last year, and have no patent concerns in the short run.

Jun 23, 2014 by Brian Wilson

Exceptional Growth in the Research Supply Industry

If we go all the way back to 1994, we can see that SIAL and TMO appreciated by 905% and 620% - beating the 343% returns seen on the S&P 500.

Jun 17, 2014 by Brian Wilson

Why This "Worst Deal" Could Work

Merck has been taking heat for the price it paid for Idenix -- Here's why it actually isn't as crazy as it sounds.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services